Form 4 for VKTX Viking Therapeutics, Inc.

Accepted 2026-07-29 20:06:00 ET · period of report 2026-07-28 · accession 0001193125-26-324446 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2026-07-29 20:06	2026-07-28	VKTX	Mancini Marianna	COO	A - Grant	$0.00	+31.7K	441.0K	+8%	$0
	2026-07-29 20:06	2026-07-29	VKTX	Mancini Marianna	COO	S - Sale	$33.47	-18.2K	422.8K	-4%	-$609.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, par value $0.00001 per share	2026-07-28	A	A	31,667	$0.00	440,977	D	—	—	(F1) The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. (F2) Includes 120 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan.
2	Common	Common Stock, par value $0.00001 per share	2026-07-29	S	D	18,217	$33.47	422,760	D	—	—	(F3) These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.